Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Recurrence 2Lymphoma, T-Cell, Peripheral 2Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Polycystic Ovary Syndrome 1Ovarian Neoplasms 1Meningeal Carcinomatosis 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell 1Lymphoma 1Lung Neoplasms 1Leukemia 1Insulin Resistance 1Infertility 1Immunoblastic Lymphadenopathy 1Hodgkin Disease 1Fallopian Tube Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

romidepsin 7N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6Vincristine 4Gemcitabine 4Doxorubicin 4Cyclophosphamide 4Prednisone 3Lenalidomide 3Azacitidine 310-propargyl-10-deazaaminopterin 3pembrolizumab 2ixazomib 2fludarabine phosphate 2copanlisib 2Whole-Body Irradiation 2Vitamin B 12 2Peripheral Blood Stem Cell Transplantation 2Nivolumab 2Mycophenolic Acid 2Folic Acid 2Etoposide 2Dexamethasone 2Cyclosporine 2Bortezomib 2venetoclax 1tislelizumab 1tazemetostat 1relatlimab 1prednisolone phosphate 1pomalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma, T-Cell, Peripheral × Folic Acid × Clear all
NCT00481871 2020-01-07

Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies

Acrotech Biopharma Inc.

Phase 1/2 Completed
119 enrolled 13 charts
LymphoidOther hematologic neoplasm

Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Recurrence, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Extranodal NK-T-Cell

NCT02013362 2017-11-09

Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Mundipharma K.K.

Phase 1/2 Completed
25 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡